Completed PHASE4 NCT00232908

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

An Open-label Study of a HAART (Highly Active Antiretroviral Therapy) Regimen Containing Subcutaneous Injection of Fuzeon on Quality of Life in Clinically Stable, Treatment-experienced Patients With HIV-1 Infection

Sponsor: Hoffmann-La Roche

Conditions HIV Infections

Interventions ARV regimen enfuvirtide [Fuzeon]

Updated 7 times since 2017 Last updated: Nov 1, 2016 Started: Jun 30, 2004 Primary completion: Oct 31, 2005 Completion: Oct 31, 2005

This PHASE4 trial investigates HIV Infections and is currently completed. Hoffmann-La Roche leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Atlanta, United States , Austin, United States , Bakersfield, United States , Bay Pines, United States , Berkeley, United States , Berkley, United States , Boise, United States , Boynton Beach, United States , Brandon, United States and 74 more locations